Peripheral Vascular Devices Market Is Projected To Reach A Valuation Of US$ 16.83 Billion By 2033

The peripheral vascular devices market refers to the medical devices used for the diagnosis and treatment of diseases related to the blood vessels outside of the heart, such as those in the arms, legs, and abdomen. The market includes devices such as stents, angioplasty balloons, atherectomy devices, catheters, and vascular closure devices, among others.

Expanding at a CAGR of 4.5%, the global peripheral vascular devices market is projected to increase from a valuation of US$ 10.84 billion in 2023 to US$ 16.83 billion by the end of 2033. The market can be segmented based on product type, application, end-user, and geography. North America dominates the market, followed by Europe and Asia Pacific. The increasing adoption of advanced technologies and the growing demand for minimally invasive surgeries are expected to further boost the market growth in these regions.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.factmr.com/connectus/sample?flag=S&rep_id=8329?Pj

𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐏𝐞𝐫𝐢𝐩𝐡𝐞𝐫𝐚𝐥 𝐕𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐭𝐮𝐝𝐲:

• The report provides a present market outlook on Peripheral Vascular Devices. Additionally, the Peripheral Vascular Devices market share is anticipated to grow with a CAGR of 4.5% in the forecast period.
• Regional breakdown of the Peripheral Vascular Devices market based on predefined taxonomy.
• Innovative manufacturing processes implemented by Peripheral Vascular Devices vendors in detail.
• Region-wise and country-wise fragmentation of the Peripheral Vascular Devices market to grasp the revenue, and growth outlook in these areas.
• Changing preferences among consumers across various regions and countries.
• Factors (Positive and Negative) impacting the growth of the global Peripheral Vascular Devices market.
• Peripheral Vascular Devices price, market share, and Trends forecast for assessment period 2023-2033

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐃𝐞𝐦𝐚𝐧𝐝 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝐟𝐨𝐫 𝐏𝐞𝐫𝐢𝐩𝐡𝐞𝐫𝐚𝐥 𝐕𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐈𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐏𝐫𝐨𝐜𝐞𝐝𝐮𝐫𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬?

Peripheral Vascular Intervention (PVI) is a minimally invasive treatment for peripheral arterial disease (PAD) that involves using catheters and stents to open blocked or narrowed arteries in the legs or other peripheral arteries. The demand for PVI treatment procedures in the United States has been growing steadily over the past decade due to the aging population, rising prevalence of PAD, and increasing awareness of minimally invasive treatments.

The global PVI market is projected to grow at a CAGR of 6.6% from 2018 to 2023, driven by the increasing incidence of PAD and technological advancements in PVI devices. In the United States, the demand for PVI procedures is expected to continue to grow, driven by the aging population and rising prevalence of PAD.

However, the COVID-19 pandemic has impacted the demand for PVI procedures and other elective surgeries in the United States due to the temporary suspension of non-emergency medical procedures and reduced patient visits to hospitals and clinics. As the pandemic subsides and healthcare services return to normalcy, the demand for PVI procedures is expected to recover.

Overall, the demand outlook for PVI treatment procedures in the United States is positive, driven by the increasing prevalence of PAD and technological advancements in PVI devices. However, the COVID-19 pandemic has temporarily disrupted the demand for elective medical procedures, including PVI procedures.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬

In September 2021, Abbott announced the purchase of Walk Vascular, an LLC that manufactures medical equipment that include a minimally-invasive mechanical aspiration peripheral venous thrombectomy device for the removal of peripheral blood clots. Abbott's current endovascular product portfolio includes Walk Vascular's peripheral thrombectomy systems. Abbott's peripheral vascular devices and accessories were expanded as a result of the collaboration.

• Cardio Flow, Inc., a producer of minimally invasive peripheral vascular devices for the treatment of peripheral artery disease, announced in June 2022 that the FDA has approved the FreedomFlow Peripheral Guidewire.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝

• Abbott Laboratories
• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Biosensors International Group Ltd.
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cordis Corporation
• iVascular S.L.U
• Medtronic PLC
• Terumo Corporation

What insights does the Peripheral Vascular Devices report provide to the readers?

• Peripheral Vascular Devices fragmentation on the basis of product type, end use, and region.
• Comprehensive assessment of upstream starting materials, downstream demand, and present market landscape.
• Collaborations, R&D projects, acquisitions, and product launches of each Peripheral Vascular Devices
• Various regulations imposed by the governments on the consumption of Peripheral Vascular Devices in detail.

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐏𝐞𝐫𝐢𝐩𝐡𝐞𝐫𝐚𝐥 𝐕𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

• By Type :

• Angioplasty Stents
• Angioplasty Balloon Catheters
• Endovascular Aneurysm Repair (EVAR) Stent Grafts
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Inferior Vena Cava Filters

• By Indication :

• Target Artery Instabilities (TAIs)
• Access Artery Injuries (AAIs)
• Peripheral Arterial Diseases
• Arteriovenous Fistulas
• Peripheral Aneurysms

• By End User :

• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Labs

• By Region :

• North America
• Latin America
• Europe
• East Asia
• South Asia & Oceania
• MEA

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:https://www.factmr.com/connectus/sample?flag=RC&rep_id=8329?PJ

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Fact.MR is a market research and consulting firm with deep expertise in emerging market intelligence. Ranging from Automotive and Industry 4.0 to Healthcare, Technology, Chemicals, Materials and even the most niche categories.

This release was published on openPR.